Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

December 29, 2023

https://www.globenewswire.com/news-release/2023/12/28/2801700/0/en/Silo-Pharma-and-Partner-Receive-Regulatory-Approval-to-Begin-Development-of-Ketamine-Implant-for-Fibromyalgia.html

Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic

SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq:SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its dosage and time-release ketamine-loaded implant, designated as SP-26, which is being developed as a potential at-home pain relief treatment for fibromyalgia and other chronic pain conditions. In collaboration with Sever Pharma Solutions, Silo’s contract development and manufacturing partner, SP-26 is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.

Read more at globenewswire.com

Related news for (SILO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.